Sign In
Buy ABBV
$217.07
+1.64 (+0.761%)
At Close: Jun 03, 2026
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:01am, Monday, 09'th Mar 2026
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
ABBV-295 treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 (weekly dosing), to -7.86% to -9.73% at week 13 (every other week and monthl
David Ryan Purdue Sells 5,230 Shares of AbbVie (NYSE:ABBV) Stock
05:14am, Sunday, 08'th Mar 2026
AbbVie Inc. (NYSE: ABBV - Get Free Report) SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233
AbbVie (ABBV) Up 6.1% Since Last Earnings Report: Can It Continue?
12:32pm, Friday, 06'th Mar 2026
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?
Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?
08:41am, Friday, 06'th Mar 2026
ABBV's neuroscience unit delivered $10.8B in 2025 and can hit $12.5B in 2026 as Vyalev gains traction and new Parkinson's drug tavapadon awaits FDA review.
These 3 Cash Flow Machines Provide Stability in Uncertain Markets
08:26am, Friday, 06'th Mar 2026
When times get tough for companies, cash flow is an essential element that can determine viability through a challenging market. Simply put, if a firm does not have the ability to meet its near-term o
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
06:45pm, Thursday, 05'th Mar 2026
In the most recent trading session, AbbVie (ABBV) closed at $232.35, indicating a -1.63% shift from the previous trading day.
AbbVie: The Only Big Pharma Stock I'd Consider a Buy‑and‑Never‑Sell
08:40am, Wednesday, 04'th Mar 2026
AbbVie had 10 therapies with sales of $1 billion or more each in 2025. The pharma giant has raised its dividends annually for 54 consecutive years.
AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
02:02am, Wednesday, 04'th Mar 2026
AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
February Dividends With 4 Raises: 1.6% Up To 14.5%
08:14am, Tuesday, 03'rd Mar 2026
Rose's Income Garden portfolio reached an all-time high, with forward yield dipping slightly to 6% as portfolio value increased. Mastercard stands out with a 14.5% dividend raise, attractive valuation
AbbVie to Present at the Leerink Partners Global Healthcare Conference
08:00am, Tuesday, 03'rd Mar 2026
NORTH CHICAGO, Ill., March 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026.
AbbVie Says 55% Of Crohn's Patients Reached Remission With Skyrizi, Bolsters Competitive Positioning Against Johnson & Johnson
12:28pm, Monday, 02'nd Mar 2026
AbbVie says 55% of Crohn's patients reached remission in a late-stage study, boosting Skyrizi's outlook amid market competition.
Why AbbVie Stock May Be the Ultimate Option for Dividend Investors
12:00pm, Monday, 02'nd Mar 2026
AbbVie has grown its dividend by more than 330% since it became a public company in 2013. It generates strong free cash flow, which leaves room for more rate hikes in the future.
In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn's disease, risankizumab (SKYRIZI®) achieved superiority for the co-primary and ranked secondary endpoints at week 12 fo
Bahl & Gaynor Inc. Has $730.34 Million Stock Holdings in AbbVie Inc. $ABBV
05:12am, Monday, 02'nd Mar 2026
Bahl and Gaynor Inc. cut its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 23.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchan
